Pacific Biosciences of California, Inc.
NASDAQ:PACB · NASDAQ Global Select
+$0.04 today
Vol 4.18M · Avg 6.06M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:PACB · Revenue to Net Income
Key Ratios
Analysis
$160.0M of revenue converted into -$128.6M of net income for the selected period. Gross margin is 37.0% and net margin is -79.2%, showing how much revenue survives after costs and taxes. EPS is $-0.43, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $160.0M +3.9% | $154.0M -23.2% | $200.5M +56.3% | $128.3M -1.7% | $130.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $109.3M -6.3% | $116.7M -21.0% | $147.7M +86.4% | $79.3M +10.6% | $71.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $50.7M +35.9% | $37.3M -29.4% | $52.8M +7.6% | $49.0M -16.7% | $58.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 31.7% +7.5pp | 24.2% -2.1pp | 26.3% -11.9pp | 38.2% -6.9pp | 45.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $97.3M -27.9% | $134.9M -27.9% | $187.2M -3.0% | $193.0M +70.9% | $112.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $141.5M -19.2% | $175.0M +3.1% | $169.8M +5.6% | $160.9M +29.6% | $124.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $608.2M +18.9% | $511.6M +32.1% | $387.2M +8.7% | $356.2M +32.3% | $269.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $504.9M +846.4% | $53.4M +63.2% | $32.7M +88.8% | $17.3M +49.5% | $11.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$34.2M +85.9% | -$242.8M +10.5% | -$271.1M +3.9% | -$282.2M -12.6% | -$250.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -21.4% +136.3pp | -157.6% -22.4pp | -135.2% +84.8pp | -220.0% -27.8pp | -192.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$557.6M -17.6% | -$474.3M -41.8% | -$334.5M -8.9% | -$307.2M -46.0% | -$210.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -348.5% -40.5pp | -308.0% -141.2pp | -166.8% +72.6pp | -239.4% -78.2pp | -161.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $7.0M -48.2% | $13.4M -6.5% | $14.3M -2.4% | $14.7M +17.2% | $12.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $11.5M -93.0% | $164.8M +910.4% | $16.3M +331.3% | -$7.1M +89.1% | -$64.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$546.1M -76.4% | -$309.5M +2.7% | -$318.2M -1.2% | -$314.2M -14.3% | -$274.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -341.3% -140.3pp | -201.0% -42.3pp | -158.7% +86.3pp | -244.9% -34.3pp | -210.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $318.0K +0.6% | $316.0K +102.8% | -$11.4M | $0 +100.0% | -$93.6M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$546.4M -76.3% | -$309.9M -1.0% | -$306.7M +2.4% | -$314.2M -73.4% | -$181.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -341.5% -140.3pp | -201.2% -48.2pp | -153.0% +92.0pp | -244.9% -106.1pp | -138.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 -61.1% | -$1 +6.6% | -$1 +13.6% | -$1 -57.3% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 -70.1% | -$1 +11.6% | -$1 +13.6% | -$1 -57.3% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $300.0M +9.3% | $274.5M +8.2% | $253.6M +12.9% | $224.6M +10.3% | $203.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $300.0M +4.0% | $288.4M +13.7% | $253.6M +12.9% | $224.6M +10.0% | $204.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Butterfly Network, Inc.
NYSE:BFLY
$1.98B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.40B
Integra LifeSciences Holdings Corporation
NASDAQ:IART
$1.38B
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
SI-BONE, Inc.
NASDAQ:SIBN
$701.72M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$577.80M
Fulgent Genetics, Inc.
NASDAQ:FLGT
$513.20M
Orthofix Medical Inc.
NASDAQ:OFIX
$371.56M
DarioHealth Corp.
NASDAQ:DRIO
$50.74M
POMDOCTOR Ltd
POM
$9.23M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PACB generate?
Pacific Biosciences of California, Inc. (PACB) reported $160.00M of revenue in fiscal 2025.
Is PACB profitable?
Pacific Biosciences of California, Inc. (PACB) reported -$546,376,000.00 of net income, with a net margin of -341.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.